- Patients currently under treatment with Retacrit™ (epoetin zeta) administered
subcutaneously for renal anaemia.
- Informed consent given in writing after being provided with detailed information about
the characteristics of this observation by the physician.
- Patients expected to be available for 3 years of observation
- Any contraindications as per the current Summary of Product Characteristics (SPC) of